ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High

Net Cost Of Alzheimer’s Drug May Still Be Within Range

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.

Cog Gear Wheel with arrows on the technology abstract background
Leqembi's final cost may still fall within ICER's recommended range • Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) issued its revised evidence report on 1 March assessing the clinical effectiveness and value of Eisai Co., Ltd./Biogen, Inc.’s Alzheimer’s therapy Leqembi (lecanemab), which slightly increased the price range it deemed cost effective for the amyloid protofibril-clearing antibody from $8,500-$20,600 in a draft assessment issued in December to a new range of $8,900-$21,500 – still $5,000 below the $26,500 annual list price set by Eisai early this year.

It is likely that the net price of Leqembi ultimately will end up within the cost-effective range outlined by ICER,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains